富马西林
生物化学
化学
生物
立体化学
癌症研究
血管生成
作者
Shenping Liu,Joanne Widom,Christopher W. Kemp,Craig M. Crews,Jon Clardy
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:1998-11-13
卷期号:282 (5392): 1324-1327
被引量:434
标识
DOI:10.1126/science.282.5392.1324
摘要
The fungal metabolite fumagillin suppresses the formation of new blood vessels, and a fumagillin analog is currently in clinical trials as an anticancer agent. The molecular target of fumagillin is methionine aminopeptidase-2 (MetAP-2). A 1.8 Å resolution crystal structure of free and inhibited human MetAP-2 shows a covalent bond formed between a reactive epoxide of fumagillin and histidine-231 in the active site of MetAP-2. Extensive hydrophobic and water-mediated polar interactions with other parts of fumagillin provide additional affinity. Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1, and the three-dimensional structure also indicates the likely determinants of this specificity. The structural basis for fumagillin's potency and specificity forms the starting point for structure-based drug design.
科研通智能强力驱动
Strongly Powered by AbleSci AI